TOFFOLETTI, Eleonora
 Distribuzione geografica
Continente #
NA - Nord America 2.403
EU - Europa 649
AS - Asia 215
AF - Africa 8
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
SA - Sud America 1
Totale 3.281
Nazione #
US - Stati Uniti d'America 2.393
UA - Ucraina 194
CN - Cina 116
IT - Italia 112
DE - Germania 88
SE - Svezia 71
FI - Finlandia 59
SG - Singapore 37
IE - Irlanda 35
TR - Turchia 35
FR - Francia 22
GB - Regno Unito 20
BE - Belgio 14
VN - Vietnam 14
IN - India 9
CA - Canada 8
CZ - Repubblica Ceca 7
EG - Egitto 6
RO - Romania 4
RU - Federazione Russa 4
AT - Austria 3
BG - Bulgaria 3
CH - Svizzera 3
EU - Europa 3
AU - Australia 2
ES - Italia 2
JP - Giappone 2
KR - Corea 2
PL - Polonia 2
RS - Serbia 2
TG - Togo 2
BR - Brasile 1
GL - Groenlandia 1
HR - Croazia 1
HU - Ungheria 1
LI - Liechtenstein 1
MX - Messico 1
NL - Olanda 1
Totale 3.281
Città #
Woodbridge 298
Ann Arbor 284
Chandler 251
Fairfield 238
Houston 172
Ashburn 138
Jacksonville 130
Seattle 108
Wilmington 89
Dearborn 86
Beijing 76
Cambridge 66
Udine 53
Boardman 47
Princeton 36
Dublin 35
Izmir 35
Singapore 29
Trieste 22
San Diego 17
Brussels 14
Dong Ket 14
Des Moines 11
Dallas 10
Ogden 10
New York 8
Redmond 8
Kunming 6
Cairo 5
Grafing 5
Hefei 5
Los Angeles 5
Milan 5
Norwalk 5
Ottawa 5
Phoenix 5
Helsinki 4
Munich 4
Nanjing 4
Prague 4
Atlanta 3
Frankfurt am Main 3
Ningbo 3
Sofia 3
Toronto 3
Vienna 3
Washington 3
Zurich 3
Belgrade 2
Brno 2
Chengdu 2
Guangzhou 2
Hebei 2
Horia 2
Hyderabad 2
Jiaxing 2
Licata 2
Lomé 2
Madrid 2
Pune 2
Shanghai 2
Simi Valley 2
Tokyo 2
Valdobbiadene 2
Warsaw 2
Wuhan 2
Adelaide 1
Amsterdam 1
Baotou 1
Birmingham 1
Bucharest 1
Budapest 1
Catanzaro 1
Cavarzere 1
Chicago 1
Clifton 1
Codroipo 1
Drap 1
Edinburgh 1
Fayetteville 1
Fuzhou 1
Jinan 1
Jinhua 1
Lanzhou 1
Leawood 1
London 1
Marseille 1
Mountain View 1
Nuuk 1
Olomouc 1
Padova 1
Perth 1
Raleigh 1
Reston 1
Saint Petersburg 1
Schaan 1
Scuola 1
Secaucus 1
Sestri Levante 1
São Paulo 1
Totale 2.441
Nome #
BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients 173
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. 144
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 134
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia 133
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 132
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 128
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. 127
Single step multiple genotyping by MALDI-TOF mass spectrometry, for evaluation of minor histocompatibility antigens in patients submitted to allogeneic stem cell transplantation from HLA-matched related and unrelated donor 121
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 120
Clonality and phenotype in spleens from patients with primary immune thrombocytopenia. 118
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. 115
B-cell immune reconstitution after allogenic stem cell transplantation and its role in the development of chronic graft-versus-host disease 113
null 111
Longitudinal follow-up of WT1 gene expression as monitoring of minimal residual disease in acute myeloid leukemia following allogeneic bone marrow transplant 109
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 108
Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. 103
Targeting kinase-activating genetic lesions to improve therapy of pediatric acute lymphoblastic leukemia 103
The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations. 102
Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia 98
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission 98
CONCOMITANT BCRP OVER-EXPRESSION AND FLT3-ITD MUTATION IDENTIFY A SUBSET OF ACUTE MYELOID LEUKEMIA PATIENTS AT HIGH RISK OF RELAPSE 89
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 88
KIR POLYMORPHISM IN REDUCED INTENSITY HLA-ID SIBLING STEM CELL TRANSPLANTATION: IMPACT ON CLINICAL OUTCOME 88
KERATOCONJUNCTIVITIS TREATMENT WITH AUTOLOGOUS SERUM EYE IN PATIENTS WITH SEVERE CHRONIC GVHD 79
No evidence for B-cell clonality by spectratyping analysis in patients with idiopathic thrombocytopenic purpura undergoing rituximab therapy” 76
Fludarabine-based induction therapy does not overcome the negative effect of bcrp (ABCG2) overexpression on remission duration in adult de novo acute myeloid leukemia patients 64
OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANT FOR REFRACTORY AND RELAPSED ACUTE MYELOID LEUKEMIA 62
Longitudinal follow up of WT1 gene expression as monitoring of minimal residual disease in acute myeloid leukemia following allogenic bone marrow transplant 61
MONITORING OF MINIMAL RESIDUAL DISEASE BY QUANTITATIVE WT1 GENE EXPRESSION AFTER REDUCED INTENSITY CONDITIONING ALLOGENEIC SCT IN ACUTE MYELOID LEUKEMIA 59
QUANTITATIVE ANALYSIS OF MN1 GENE EXPRESSION FOR EVALUATION OF MINIMAL RESIDUAL DISEASE IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA PATIENTS 57
CONCOMITANT OVEREXPRESSION OF BCRP AND FLT3-ITD MUTATION ARE ASSOCIATED WITH POOR PROGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS 52
Clinical presentation, outcome and risk factors of late-onset non-infectious pulmonary complication after allogeneic transplantation 52
Monitoring of minimal residual disease by quantitative WT1 gene expression following reduce intensity conditioning allogenic stem cell transplantation in acute myeloid leukaemia 50
MULTICENTER PROSPECTIVE CLINICAL TRIAL WITH LOW DOSE GEMTUZUMAB-OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN (GO-FLAI) AS INDUCTION THERAPY OF CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS YOUNGER THAN 65 YEARS 40
WT1 – Gene expression driven pre-emptive treatment with decitabine for molecular relapse of acute myeloid leukemia after allogeneic stem cell transplant 31
JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response 25
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment-free remission: A study from the “GRUPPO TRIVENETO LMC” 17
A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity in vitro: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias 14
Optimal timing of molecular monitoring after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia 9
Expression and modulation of S100A4 protein by human mast cells 1
Totale 3.404
Categoria #
all - tutte 10.786
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.786


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020717 0 0 27 129 58 131 84 88 55 73 19 53
2020/2021479 10 44 11 51 15 49 27 47 85 21 87 32
2021/2022368 18 35 16 21 22 9 22 10 10 54 96 55
2022/2023531 52 48 5 80 48 116 3 61 71 11 24 12
2023/2024143 19 16 5 4 20 18 2 8 14 8 7 22
2024/202578 23 55 0 0 0 0 0 0 0 0 0 0
Totale 3.404